jRCT2031250732尚未招募不适用
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (A Phase 1/2 First-Time-in-Human study of GSK5471713 in adults with mCRPC)
未提供0 个研究点目标入组 54 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- Male
入选标准
- •Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.
- •Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
- •Eastern Cooperative Oncology Group performance status 0 or
- •Progression on ADT and >=1 prior Androgen receptor pathway inhibitors for Hormone-Sensitive Prostate Cancer or Castration resistant prostate cancer and received 1-2 prior taxane based chemotherapy regimens.
排除标准
- •Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.
- •Impaired cardiac function or clinically significant cardiac disease.
- •Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.
- •Prior therapy with Androgen receptor degrader targeted therapy.
- •Other protocol-defined inclusion/exclusion criteria apply.
研究者
相似试验
已完成
1 期
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP2024-511493-67-00Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts45
撤回
2 期
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bifunctional Antibody-fusion molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-Rich (START-001)2023-505334-10-00Marengo Therapeutics Inc.46
已完成
2 期
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors2023-505576-29-00Centessa Pharmaceuticals UK Limited6